Alpha blocker + placebo + solifenacin
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Urinary Bladder, Overactive
Conditions
Urinary Bladder, Overactive
Trial Timeline
Jun 1, 2008 โ Mar 1, 2010
NCT ID
NCT00699049About Alpha blocker + placebo + solifenacin
Alpha blocker + placebo + solifenacin is a approved stage product being developed by Astellas Pharma for Urinary Bladder, Overactive. The current trial status is completed. This product is registered under clinical trial identifier NCT00699049. Target conditions include Urinary Bladder, Overactive.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00699049 | Approved | Completed |
Competing Products
20 competing products in Urinary Bladder, Overactive